27.78  0.52 (1.91%)		11-11 16:00
Open: 26.935 High: 27.92 Volume: 2,354,394		Pre. Close: 27.26 Low: 26.64 Market Cap: 2,374(M)

Short term
Mid term
Targets	6-month :	33.89	1-year :	39.58
Resists	First :	29.01	Second :	33.89
Pivot price	24.59
Supports	First :	24.64	Second :	21.94
MAs	MA(5) :	26.63	MA(20) :	24.28
	MA(100) :	21.84	MA(250) :	17.1
MACD	MACD :	0.9	Signal :	0.4
%K %D	K(14,3) :	72.1	D(3) :	63.9
RSI	RSI(14): 64
52-week	High :	29.94	Low :	9.71

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ LQDA ] has closed below upper band by 11.4%. Bollinger Bands are 40.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	27.96 - 28.07	28.07 - 28.19
Low:	26.37 - 26.48	26.48 - 26.6
Close:	27.59 - 27.79	27.79 - 28

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Mon, 10 Nov 2025
Chief Medical Officer Of Liquidia Sold 60% Of Their Shares - simplywall.st

Sat, 08 Nov 2025
Rajeev Saggar Sells 71,381 Shares of Liquidia (NASDAQ:LQDA) Stock - MarketBeat

Fri, 07 Nov 2025
A Look at Liquidia’s (LQDA) Valuation Following Strong YUTREPIA Launch and First Profitable Quarter - simplywall.st

Fri, 07 Nov 2025
Liquidia Corporation (NASDAQ:LQDA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Thu, 06 Nov 2025
Liquidia (LQDA) Is Up 17.7% After Yutrepia Drives Record Revenue and Early Market Adoption - Sahm

Thu, 06 Nov 2025
Wall Street Analysts Think Liquidia Corporation (LQDA) Could Surge 62.34%: Read This Before Placing a Bet - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	86 (M)
Shares Float	61 (M)
Held by Insiders	13.3 (%)
Held by Institutions	70.5 (%)
Shares Short	17,820 (K)
Shares Short P.Month	18,470 (K)

EPS	-1.83
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.18
Profit Margin	0 %
Operating Margin	-424.5 %
Return on Assets (ttm)	-39.8 %
Return on Equity (ttm)	-389.2 %
Qtrly Rev. Growth	141.5 %
Gross Profit (p.s.)	0.15
Sales Per Share	0.22
EBITDA (p.s.)	-1.59
Qtrly Earnings Growth	0 %
Operating Cash Flow	-116 (M)
Levered Free Cash Flow	-71 (M)

PE Ratio	-15.27
PEG Ratio	0
Price to Book value	154.33
Price to Sales	123.78
Price to Cash Flow	-20.61

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.